Think Research Corporation (TSX-V:THNK) has announced that its MDBriefcase Group Inc subsidiary has been chosen by a global pharmaceutical company to deliver high-quality content to healthcare practitioners and allied health professionals regarding its drug and vaccine therapies.
The company said MDBriefCase will deliver programming throughout 2022 and 2023 under the contract, which has a total value of approximately $4.1 million, with revenues to be earned based on the achievement of various contractual milestones and the delivery of applicable programming.
The agreement encompasses Think's content solutions along with MDBriefCase's learning management system (LMS) to provide a broad offering of content, essential data services and software, it added.
READ: Think Research closes initial advance of $10 million from Beedie Investments under non-revolving term convertible loan facility
"We are pleased to be selected to provide essential content and learning solutions to healthcare practitioners on behalf of this exceptional client,” Think Research CEO Sachin Aggarwal said in a statement. “This agreement is indicative of our vision to leverage our entire suite of solutions to become an essential data service for clinicians everywhere."
Think said the agreement further enhances its Clinical Knowledge business line, which focuses on collaborative, clinical knowledge-sharing and education tools that help its clients learn, integrate and apply cutting-edge clinical research development and practice innovation into frontline clinical settings.
"This agreement enables us to support the training of health practitioners and provide the highest quality content about best-practice treatments, therapies, and pharmaceuticals to deliver optimal outcomes for patients," Aggarwal added.
With full integration of MDBriefCase into Think recently completed, the company said the LMS and accredited, online Continuing Professional Development (CPD) programs offered by MDBriefCase will help healthcare practitioners and specialists enhance their professional practice and stay at the forefront of the latest evidence and protocols.
These programs will continue to enhance the user value of Think's Clinical Knowledge offerings and broaden its market reach within the global healthcare industry, it added.
Think Research is an industry leader in delivering knowledge-based digital healthcare software solutions. The company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes.
Think serves as a trusted health system partner to a rapidly growing, global client base that spans five continents across more than 13,000 healthcare facilities, with a clinical audience of over 300,000 doctors, nurses and pharmacists.
Contact the author at stephen.gunnion@proactiveinvestors.com